Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AMYTCVE:BMKNASDAQ:FIRETSE:HLSNYSEAMERICAN:ZOM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMYTAmryt Pharma$14.70+0.1%$14.64$6.41▼$14.77$940.21M0.84757,360 shs2.39 million shsBMKMacDonald Mines ExplorationC$0.04-12.5%C$0.05C$0.03▼C$0.09C$1.33M0.475,091 shs2,000 shsFIRE(FIRE)$0.00$0.00▼$0.00N/AN/AN/AN/AHLSHLS TherapeuticsC$4.75C$4.26C$3.34▼C$7.12C$151.62M1.169,527 shs1,700 shsZOMZomedica$0.13-1.8%$0.00$0.12▼$0.25$126.41M15.20 million shs2.37 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMYTAmryt Pharma0.00%0.00%0.00%0.00%0.00%BMKMacDonald Mines Exploration0.00%-12.50%-22.22%-22.22%-36.36%FIRE(FIRE)0.00%0.00%0.00%0.00%0.00%HLSHLS Therapeutics0.00%-2.86%+23.70%+16.42%-20.83%ZOMZomedica0.00%0.00%+1.67%+4.23%-33.73%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMYTAmryt PharmaN/AN/AN/AN/AN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AN/AN/AN/AHLSHLS Therapeutics0.0571 of 5 stars1.10.01.70.00.60.80.0ZOMZomedicaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMYTAmryt PharmaN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AHLSHLS Therapeutics2.25HoldC$4.58-3.68% DownsideZOMZomedicaN/AN/AN/AN/ACurrent Analyst RatingsLatest BMK, ZOM, AMYT, FIRE, and HLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2024HLSHLS TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$6.50 ➝ C$5.003/15/2024HLSHLS TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$4.35 ➝ C$4.152/22/2024HLSHLS TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$5.00 ➝ C$4.352/6/2024HLSHLS TherapeuticsClarus SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMYTAmryt Pharma$222.54M4.22$0.98 per share14.98$5.58 per share2.63BMKMacDonald Mines ExplorationC$-74K-17.92C$0.00 per share13.00C($0.01) per share-3.50FIRE(FIRE)N/AN/AN/AN/AN/AN/AHLSHLS TherapeuticsC$63.07M2.40C$0.31 per share15.22C$3.06 per share1.55ZOMZomedica$25.19M5.02N/AN/A$0.24 per share0.54Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMYTAmryt Pharma$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/ABMKMacDonald Mines Exploration-C$1.28M-C$0.02N/A∞N/AN/A-1,679.48%-324.12%6/4/2024 (Estimated)FIRE(FIRE)N/AN/A0.00N/AN/AN/AN/AN/AN/AHLSHLS Therapeutics-C$27.53M-C$1.16N/A∞N/A-43.65%-24.69%-2.87%5/9/2024 (Estimated)ZOMZomedica-$34.53M-$0.04N/A∞N/A-137.10%-8.13%-7.68%5/9/2024 (Estimated)Latest BMK, ZOM, AMYT, FIRE, and HLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ZOMZomedicaN/A-$0.01-$0.01N/A$7.00 million$7.34 million 3/14/2024Q4 2023HLSHLS Therapeutics-C$0.13-C$0.18-C$0.05-C$0.13C$21.83 millionC$21.60 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMYTAmryt PharmaN/AN/AN/AN/AN/ABMKMacDonald Mines ExplorationN/AN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AHLSHLS TherapeuticsC$0.204.21%N/AN/A N/AZOMZomedicaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMYTAmryt Pharma0.641.570.94BMKMacDonald Mines Exploration3.840.220.27FIRE(FIRE)N/AN/AN/AHLSHLS Therapeutics89.691.651.01ZOMZomedicaN/A11.0610.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMYTAmryt Pharma71.31%BMKMacDonald Mines Exploration1.10%FIRE(FIRE)N/AHLSHLS Therapeutics59.62%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipAMYTAmryt Pharma5.66%BMKMacDonald Mines Exploration7.58%FIRE(FIRE)N/AHLSHLS Therapeutics0.49%ZOMZomedica4.18%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMYTAmryt Pharma2,02063.96 million60.34 millionNot OptionableBMKMacDonald Mines Exploration237.88 millionN/ANot OptionableFIRE(FIRE)N/AN/AN/ANot OptionableHLSHLS Therapeutics9131.92 millionN/ANot OptionableZOMZomedica144979.95 million938.99 millionNot OptionableBMK, ZOM, AMYT, FIRE, and HLS HeadlinesSourceHeadlineWhat’s Happening at the Defender Kentucky Three Day Eventeventingnation.com - April 21 at 12:53 PMZomedica (NYSEAMERICAN:ZOM) Stock Price Down 4.3%americanbankingnews.com - April 21 at 6:12 AMZomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024accesswire.com - April 9 at 6:30 AMZomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call Transcriptmsn.com - April 2 at 4:06 PMQ4 2023 Zomedica Corp Earnings Callfinance.yahoo.com - April 2 at 8:30 AMZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023investorplace.com - April 1 at 9:06 PMZomedica reports Q4 resultsmsn.com - April 1 at 5:27 PMZomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidityaccesswire.com - April 1 at 4:05 PMThe Next Millionaire-Makers: 3 Penny Stocks With Massive Upside Potentialinvestorplace.com - April 1 at 3:12 PMZomedica to Report Fourth Quarter and Full Year 20…pharmiweb.com - March 20 at 9:17 AMZomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ETaccesswire.com - March 20 at 6:30 AMZomedica Pharmaceuticals Corp (ZOM)investing.com - March 15 at 7:52 AMZomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platformaccesswire.com - March 14 at 6:30 AMZomedica Provides NYSE American Listing Updateaccesswire.com - March 13 at 4:45 PMSidoti & Company, LLC: Sidoti Events, LLC's Virtual March Small-Cap Conferencefinanznachrichten.de - March 12 at 11:26 AMZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesfinanznachrichten.de - March 12 at 8:22 AMZomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesaccesswire.com - March 12 at 6:30 AMZomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogsaccesswire.com - March 7 at 6:30 AMZomedica to Present at the Sidoti Small Cap Conference March 14, 2024accesswire.com - March 5 at 6:30 AMZomedica Pharmaceuticals Corp. (ZOM)uk.finance.yahoo.com - March 1 at 2:46 PMZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferencesfinanznachrichten.de - February 8 at 9:14 AMZomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferencesfinance.yahoo.com - February 8 at 9:14 AMZomedica Corp.: Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidationfinanznachrichten.de - February 6 at 5:00 PMLeading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)finance.yahoo.com - February 6 at 5:00 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeASML Fires Warning Shot For Tech InvestorsApril 17, 2024 9:05 AMView ASML Fires Warning Shot For Tech InvestorsMissed Taiwan Semi’s Rise? Try United Microelectronics April 17, 2024 7:00 AMView Missed Taiwan Semi’s Rise? Try United Microelectronics All Headlines Company DescriptionsAmryt PharmaNASDAQ:AMYTAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.MacDonald Mines ExplorationCVE:BMKMacDonald Mines Exploration Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company explores for gold, silver, copper, cobalt, and nickel deposits. It owns 100% interest in the Scadding-Powerline-Jovan property that covers an area of 19,710 hectares located to the east of Sudbury in Northern Ontario. The company was formerly known as MacDonald Mines Limited. MacDonald Mines Exploration Ltd. was incorporated in 1936 and is based in Toronto, Canada.(FIRE)NASDAQ:FIRESourcefire, Inc. (Sourcefire) is engaged in the business of delivering intelligent cybersecurity technologies. The Company provides a portfolio of solutions that enables commercial enterprises and government agencies worldwide to manage and minimize cybersecurity risks. Sourcefire provides customers with Agile Security that consists of hardware with embedded software, software and cloud-based solutions. It sells its solutions to a customer base that includes Global 2000 companies, global enterprises, the United States and international government agencies, and small and mid-size businesses. During the year ended December 31, 2012, it generated approximately 67% of the Company's revenue from customers in the United States, and 33% of the Company's revenue from customers outside of the United States. As of December 31, 2012, its product revenue and services revenue represented 61% and 39% of its total revenue, respectively.HLS TherapeuticsTSE:HLSHLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.ZomedicaNYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.